...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Technological forecasting and social change >The future of drug discovery and development: Shifting emphasis towards personalized medicine
【24h】

The future of drug discovery and development: Shifting emphasis towards personalized medicine

机译：药物研发的未来：将重点转移到个性化医学上

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The drug discovery sector is being revolutionized by the current rate of advances in the public and private human genome projects and by the development of new technologies for biomarker testing. In effect, as the genetic roots of disease, disease progression and treatment effectiveness are uncovered, the demand for sophisticated prognostic, diagnostic and monitoring tests will be increasing. Already this has led to the development of innovative diagnostics products meeting the criteria of improved efficacy and safety as well as better cost-benefits. In order to achieve the ultimate goal of a more predictive and personalized medicine requires the drug discovery industry to implement more synergies between the two worlds of clinical research and diagnostics. The therapeutics that are enabled by that strategy are often called "theranostics" - highly specific tests that allow for the diagnosis of the disease, but to administer the most appropriate treatment regimen, and to monitor a patient's response to therapy. Biomarkers will constitute a critical component of the health care delivery system in order to detect, diagnose and monitor diseases and other medical conditions as well as to evaluate treatment options and effectiveness. While diagnostic breakthroughs typically precede therapeutic advances, the presence of new therapies can stimulate the demand for testing. The main question that remains to be answered is how will the biomarker paradigm alters these companies' innovation and commercialization strategies. Whereas developing drug targets may offer greater long-term value, initial commercial opportunities often arise in diagnostics.
机译：当前公共和私人人类基因组项目的进展速度以及生物标志物检测新技术的发展，都使药物发现领域发生了革命性变化。实际上，随着疾病的遗传根源，疾病进展和治疗效果的发现，对复杂的预后，诊断和监测测试的需求将会增加。这已经导致开发出满足提高功效和安全性以及更好的成本效益标准的创新型诊断产品。为了实现更具预测性和个性化的医学的最终目标，药物发现行业需要在临床研究和诊断的两个世界之间实现更多的协同作用。通过该策略启用的治疗方法通常被称为“ theranostics”-高度特异性的测试，可以诊断疾病，但要执行最合适的治疗方案，并监视患者对治疗的反应。生物标志物将构成卫生保健提供系统的重要组成部分，以检测，诊断和监测疾病和其他医疗状况以及评估治疗方案和有效性。尽管诊断突破通常先于治疗进展，但新疗法的出现可以刺激对测试的需求。有待回答的主要问题是，生物标志物范例将如何改变这些公司的创新和商业化策略。制定药物靶标可能会提供更大的长期价值，而在诊断中通常会出现最初的商业机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号